Table 1.

Characteristics of children and young people receiving MMF by intravenous infusion or oral administration

Characteristics	Median	Range
Number of children and young people (MPA concentrations)	38 (859)
0 < Age (years) < 2	7 (155)
2 < Age (years) ≤ 5	4 (75)
5 < Age (years) ≤ 12	17 (376)
12 < Age (years) < 20	10 (253)
Number who had intravenous dosing	13
Number who had oral dosing	18
Number who had both intravenous and oral dosing	7
Number who had intensive sampling	13
Number who had sparse sampling	7
Number who had random sampling	18
Number who had enterohepatic recirculation	9
Transplantation type
Blood or marrow transplant	23
Kidney transplant	5
Liver transplant	10
Concomitant immunosuppressant
With ciclosporin	23
With tacrolimus	15
Concomitant antiviral
With acyclovir	9
Without acyclovir	29
Unbound fraction	0.0116	0.0049–0.06
Sex (male/female)	20/18
Age (years)	8.4	0.4–19.9
Weight (kg)	27.9	3.4–87.7
Body surface area (m2)	1.0	0.22–2.0
Body mass index (kg m−2)	17.2	11.9–31.8
Height (cm)	128.6	53.5–169.0
Creatinine clearance (l h−1 kg−1)*	0.12	0.01–0.31
Albumin (g l−1)†	31.0	22.0–44.0

Body surface area, BSA [45];

^*Creatinine clearance, CL_CR was estimated using the Counahan formula [24].

^†Serum albumin was determined using bromocresol green dye (a colorimetric method).